Adocia Publishes its Letter to Shareholders
24 November 2023 - 4:00AM
Business Wire
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical company focused on the research and development
of innovative therapeutic solutions for the treatment of diabetes
and other metabolic diseases, announced today the publication of
the November 2023 Letter to Shareholders.
Read the Letter to Shareholders by
clicking here.
You can also access the letter via the section dedicated to
investors on our website.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining insulins with other classes of hormones; 2)
AdOral®, an oral peptide delivery technology; 3) AdoShell®, an
immunoprotective biomaterial for cell transplantation, with a first
application in pancreatic cells transplantation; 4) AdoGel®, a
long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has more than 80 employees. Adocia is listed on the
regulated market of EuronextTM Paris (Euronext: ADOC; ISIN:
FR0011184241)
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the universal registration
document that was filed with the French Autorité des marchés
financiers on April 26, 2023 updated by the amendment of 26 July
2023 (D.23-0346-A01) and amendment of 13 September 2023
(D.23-0346-A02), available at www.adocia.com, in particular
uncertainties that are linked to research and development, future
clinical data, analyses, and the evolution of the economic context,
the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release
are also subject to risks not yet known to Adocia or not considered
as material by Adocia as of this day. The occurrence of all or part
of such risks could cause that actual results, financial
conditions, performances, or achievements of Adocia be materially
different from those mentioned in the forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231123916972/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication Adocia Relations Presse et
Investisseurs Pierre-Louis Germain Bruno Arabian
adocia@ulysse-communication.com + 33 (0)6 64 79 97 51
Edoc Acquisition (NASDAQ:ADOC)
Historical Stock Chart
From May 2024 to Jun 2024
Edoc Acquisition (NASDAQ:ADOC)
Historical Stock Chart
From Jun 2023 to Jun 2024